Clinical Trials Browser

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT06611540 2026-05-13

LMI-001-A-S03

Phase NA Active not recruiting

500 enrolled

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT06611553 2026-05-13

LMI-001-A-S02

Phase NA Active not recruiting

500 enrolled

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT07281430 2026-05-13

LMI-001-A-S04

Phase NA Recruiting

500 enrolled

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT07281599 2026-02-02

EQUIP

Phase NA Recruiting

450 enrolled

Gynecologic

Genital Diseases, Uterine Cervical Neoplasms, Sexually Transmitted Diseases, Sexually Transmitted Diseases, Viral, Papillomavirus Infections

NCT04794660 2024-03-13

CESTA

Phase 3 Unknown

1,500 enrolled

Papillomavirus Infections

NCT02634190 2024-02-28

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

Completed

10,000 enrolled

Papillomavirus Infections

NCT04369339 2020-04-30

Colposcopy Findings Among Women With High Risk HPV Other Than HPV 16/18 and Normal Cytology

Phase NA Completed

185 enrolled

Neoplasms, Papillomavirus Infections

NCT00977392 2013-08-07

Self-Sampling in Women Who Do Not Undergo Routine Cervical Screening

Completed

3,000 enrolled

Other neoplasm

Precancerous Conditions, Papillomavirus Infections

Clinical Trials

SHIP-A-S01

LMI-001-A-S03

LMI-001-A-S02

LMI-001-A-S04

EQUIP

CESTA

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

Colposcopy Findings Among Women With High Risk HPV Other Than HPV 16/18 and Normal Cytology

Self-Sampling in Women Who Do Not Undergo Routine Cervical Screening